Expert Interviews

Petros Grivas, MD, PhD, introduces a patient profile of a woman with metastatic UC and invites panel members to comment on how they might approach initial treatment and management of the patient.

Ira Winer, MD, PhD, FACOG, spoke about high response rates observed in patients with pretreated platinum-resistant ovarian cancer from the phase 1/2 ARTISTRY-1 trial.

Petros Grivas, MD, PhD, Shilpa Gupta, MD, Peter H. O’Donnell, MD, Thomas Powles, MBBS, MRCP, MD, and Guru Sonpavde, MD, summarize recent treatment advances for patients with urothelial cancer (UC).

Phillip S. Low, PhD, spoke about what the future holds for treatments like 177Lu-PSMA-617 being developed for patients with prostate cancer.

Panelists consider key risk factors for chronic GVHD, including the degree of donor transplant matching, patient age, intensity of conditioning, use of ablative doses of total-body radiation, and presence of acute GVHD.

Pashna N. Munshi, MD, and Yi-Bin Chen, MD, examine key differences in the pathologic features of acute and chronic GVHD.

Ursula A. Matulonis, MD, discusses key data with mirvetuximab soravtansine for patients with folate receptor α–high platinum-resistant ovarian cancer that read out of the phase 3 SORAYA trial.

Matthew Krebs, MB, PhD spoke about the reasoning for the phase 1 PALOMA trial in patients with solid tumors who received a subcutaneous formulation of amivantamab.

Shared insight on the selection of specific androgen receptor inhibitors for patients with nonmetastatic castration-resistant prostate cancer.

Centering the discussion around a patient with nonmetastatic castration-resistant prostate cancer, experts share insight on optimal work-up and testing.

Stéphane Champiat, MD, PhD, spoke about the results of the AURELIO-03 trial with SOT101 and pembrolizumab for patients with advanced solid tumors.

Shared insight on the adverse event profile of immunotherapy combination regimens in renal cell carcinoma, including advice on when it is appropriate to discontinue therapy.

Expert perspectives on the triplet combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma presented at the 2021 ASH [American Society of Hematology] Annual Meeting.

Expert perspectives on the clinical scenario of a patient with intermediate-risk renal cell carcinoma, who is managed with the immunotherapy combination of ipilimumab and nivolumab.

Continuing their discussion on the management of multiple myeloma, experts Paul Richardson, MD, and Cristina Gasparetto, MD, consider the value of minimal residual disease as a marker.

Frederick Lock, MD, spoke about the approval of axicabtagene ciloleucel and how it’s beneficial for patients with large B-cell lymphoma who were treated with frontline chemoimmunotherapy.

A prostate cancer expert discusses promising and emerging treatments for prostate cancer.

Dr Choudhury shares recent updates from 2021 meetings including ASCO GU, AUA, and ESMO.

Lori Wirth, MD, defines radioiodine-refractory differentiated thyroid cancer and discusses frontline treatment options for patients with the disease.

Hannah Choe, MD, guides the panel in a conversation on the protective effects of acute and chronic GVHD including the potential impact on leukemic relapse.